Valproate‐Induced Systemic Lupus Erythematosus in a Patient with Partial Trisomy of Chromosome 9 and Epilepsy
- 1 June 1996
- Vol. 37 (6), 587-588
- https://doi.org/10.1111/j.1528-1157.1996.tb00614.x
Abstract
We report a mentally retarded 30-year-old woman with partial trisomy of chromosome 9 (46,XX-6,+der(6)t(6,9)pat) who has had epilepsy since age 11 months. She had been treated with various combinations of drugs. After 1 year of treatment with valproate (VPA) and ethosuximide (ESM), the patient developed arthralgias, muscle weakness, fatigue, and fever. Laboratory examination showed increased sedimentation rate, hypergammaglobulinemia, and high titers of antinuclear antibodies (ANA). The possibility of VPA-induced systemic lupus erythematosus (SLE) was considered. This diagnosis was supported by detection of antihistone antibodies and the HLA-DR4 antigen. VPA dosage was tapered and discontinued, with accompanying resolution of clinical, immunological and hematological signs of SLE 6 weeks after VPA discontinuation. This is the fourth reported case of VPA-induced SLEKeywords
This publication has 7 references indexed in Scilit:
- DRUG-INDUCED LUPUSRheumatic Disease Clinics of North America, 1994
- Systemic Lupus Erythematosus Associated with Use of ValproateEpilepsia, 1994
- Carbamazepine-Induced Systemic Lupus Erythematosus-Like Disease.Internal Medicine, 1992
- Possible Induction of Systemic Lupus Erythematosus by ValproateEpilepsia, 1990
- COMPLEMENT SYSTEM PROTEIN C4 AND SUSCEPTIBILITY TO HYDRALAZINE-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUSThe Lancet, 1989
- Antinuclear Antibodies and Lupus-like Syndromes in Children Receiving AnticonvulsantsPediatrics, 1976
- Lupus-scleroderma syndrome induced by ethosuximide.Archives of Disease in Childhood, 1975